About 0 results.


Description. Lang: en

Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.One of the two Phase 3 clinical trials (Spectri) was interrupted on September 8, 2017 due to failure to meet primary end point. The second Phase 3 clinical trial (Chroma) also failed to meet its primary end point.These two failures have called into question whether complement inhibition is a sound strategy for geographic atrophy.
Description provided by Wikipedia.

Google Suggest

Search predictions are possible search terms you can use that are related to the terms you’re typing and what other people are searching for.

Entity Index

This is the list of all entities in this result page. Click an entity to go directly to the entity box.

    Wiki Authority Control

    Authority control is a method of creating and maintaining index terms for bibliographical material in a library catalogue. The links produced by the authority control template on Wikipedia go to authority control data in worldwide library catalogues.

    Google Knowledge Graph

    Try searching in other languages: en - it - fr - de - es - pt
    Entities Finder | Keyword Tool | URLs Match | Cache index

    This process used 24 ms for its computations It spent 8 ms in system calls .